MediWound (NASDAQ:MDWD) Releases Quarterly Earnings Results, Beats Expectations By $0.42 EPS

MediWound (NASDAQ:MDWD) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.42, RTT News reports. The business had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $3.37 million. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.During the same period last year, the firm earned ($0.07) earnings per share.

Here are the key takeaways from MediWound’s conference call:

• EscharEx remains the company’s main development priority, but the VALUE Phase III study has been pushed back by one quarter, with enrollment now expected to finish by the end of Q1 2027. Management said the delay was driven by operational issues in Europe and the burden of frequent wound assessments, not by safety or efficacy concerns.
• The company said its EscharEx collaboration network has expanded to include nearly all major advanced wound care players, now adding Medline. This broader industry involvement was presented as external validation of EscharEx and could support future commercialization and additional studies in DFU and pressure ulcers.
• NexoBrid continued to gain commercial and strategic traction, with Vericel reporting growth in ordering centers and total orders in the U.S. burn market. MediWound also highlighted a new 10-year BARDA contract worth up to $197 million, with procurement and development expected to begin in the second half of 2026.
• First-quarter 2026 revenue fell to $1.5 million from $4.0 million a year earlier, mainly because of the timing of BARDA-related revenue and shipment delays tied to regional conflict. The quarter also reflected higher R&D spending on the EscharEx VALUE study, contributing to a wider operating loss.
• Management reaffirmed full-year 2026 revenue guidance of $24 million to $26 million, expecting a second-half weighted ramp from government-related development services and procurement. The company said it is working through EMA pre-audit modifications at its expanded manufacturing facility and expects those activities to be completed in the second half of 2026.

MediWound Price Performance

Shares of NASDAQ MDWD opened at $14.33 on Thursday. The company has a market capitalization of $184.14 million, a price-to-earnings ratio of -6.82 and a beta of 0.21. The business has a 50-day moving average of $16.73 and a two-hundred day moving average of $17.48. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50.

Institutional Trading of MediWound

Institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in MediWound during the 4th quarter worth about $26,000. BNP Paribas Financial Markets lifted its holdings in MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in MediWound during the 4th quarter worth about $109,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MDWD. Wall Street Zen cut MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Tuesday, April 21st. Finally, Oppenheimer reiterated an “outperform” rating and issued a $32.00 price objective on shares of MediWound in a research note on Wednesday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $34.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.